These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 30253191)

  • 1. FOXF1 promotes angiogenesis and accelerates bevacizumab resistance in colorectal cancer by transcriptionally activating VEGFA.
    Wang S; Xiao Z; Hong Z; Jiao H; Zhu S; Zhao Y; Bi J; Qiu J; Zhang D; Yan J; Zhang L; Huang C; Li T; Liang L; Liao W; Ye Y; Ding Y
    Cancer Lett; 2018 Dec; 439():78-90. PubMed ID: 30253191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOXF1 Induces Epithelial-Mesenchymal Transition in Colorectal Cancer Metastasis by Transcriptionally Activating SNAI1.
    Wang S; Yan S; Zhu S; Zhao Y; Yan J; Xiao Z; Bi J; Qiu J; Zhang D; Hong Z; Zhang L; Huang C; Li T; Liang L; Liao W; Jiao H; Ding Y; Ye Y
    Neoplasia; 2018 Oct; 20(10):996-1007. PubMed ID: 30189360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A.
    Burgermeister E; Battaglin F; Eladly F; Wu W; Herweck F; Schulte N; Betge J; Härtel N; Kather JN; Weis CA; Gaiser T; Marx A; Weiss C; Hofheinz R; Miller IS; Loupakis F; Lenz HJ; Byrne AT; Ebert MP
    EBioMedicine; 2019 Jul; 45():139-154. PubMed ID: 31300350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DHX32 Promotes Angiogenesis in Colorectal Cancer Through Augmenting β-catenin Signaling to Induce Expression of VEGFA.
    Lin H; Fang Z; Su Y; Li P; Wang J; Liao H; Hu Q; Ye C; Fang Y; Luo Q; Lin Z; Pan C; Wang F; Zhang ZY
    EBioMedicine; 2017 Apr; 18():62-72. PubMed ID: 28330603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-622 inhibits angiogenesis by suppressing the CXCR4-VEGFA axis in colorectal cancer.
    Fang Y; Sun B; Wang J; Wang Y
    Gene; 2019 May; 699():37-42. PubMed ID: 30851425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5
    Feng H; Liu K; Shen X; Liang J; Wang C; Qiu W; Cheng X; Zhao R
    Cell Death Dis; 2020 Oct; 11(10):916. PubMed ID: 33099574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms.
    Wagner J; Kline CL; Zhou L; Khazak V; El-Deiry WS
    J Exp Clin Cancer Res; 2018 Jan; 37(1):11. PubMed ID: 29357916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model.
    Iwai T; Sugimoto M; Harada S; Yorozu K; Kurasawa M; Yamamoto K
    Oncol Rep; 2016 Aug; 36(2):626-32. PubMed ID: 27350037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tanshinone IIA inhibits β-catenin/VEGF-mediated angiogenesis by targeting TGF-β1 in normoxic and HIF-1α in hypoxic microenvironments in human colorectal cancer.
    Sui H; Zhao J; Zhou L; Wen H; Deng W; Li C; Ji Q; Liu X; Feng Y; Chai N; Zhang Q; Cai J; Li Q
    Cancer Lett; 2017 Sep; 403():86-97. PubMed ID: 28602978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor.
    Mésange P; Poindessous V; Sabbah M; Escargueil AE; de Gramont A; Larsen AK
    Oncotarget; 2014 Jul; 5(13):4709-21. PubMed ID: 25015210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer.
    Schiffmann LM; Fritsch M; Gebauer F; Günther SD; Stair NR; Seeger JM; Thangarajah F; Dieplinger G; Bludau M; Alakus H; Göbel H; Quaas A; Zander T; Hilberg F; Bruns CJ; Kashkar H; Coutelle O
    Br J Cancer; 2019 Jan; 120(1):69-78. PubMed ID: 30377339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B7-H3 promotes colorectal cancer angiogenesis through activating the NF-κB pathway to induce VEGFA expression.
    Wang R; Ma Y; Zhan S; Zhang G; Cao L; Zhang X; Shi T; Chen W
    Cell Death Dis; 2020 Jan; 11(1):55. PubMed ID: 31974361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P53-induced miR-1249 inhibits tumor growth, metastasis, and angiogenesis by targeting VEGFA and HMGA2.
    Chen X; Zeng K; Xu M; Liu X; Hu X; Xu T; He B; Pan Y; Sun H; Wang S
    Cell Death Dis; 2019 Feb; 10(2):131. PubMed ID: 30755600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer.
    Zhou Q; Perakis SO; Ulz P; Mohan S; Riedl JM; Talakic E; Lax S; Tötsch M; Hoefler G; Bauernhofer T; Pichler M; Gerger A; Geigl JB; Heitzer E; Speicher MR
    Genome Med; 2020 Feb; 12(1):20. PubMed ID: 32087735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
    Ding C; Li L; Yang T; Fan X; Wu G
    BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab terminates homeobox B9-induced tumor proliferation by silencing microenvironmental communication.
    Hoshino Y; Hayashida T; Hirata A; Takahashi H; Chiba N; Ohmura M; Wakui M; Jinno H; Hasegawa H; Maheswaran S; Suematsu M; Kitagawa Y
    Mol Cancer; 2014 May; 13():102. PubMed ID: 24885802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-590-5p inhibits colorectal cancer angiogenesis and metastasis by regulating nuclear factor 90/vascular endothelial growth factor A axis.
    Zhou Q; Zhu Y; Wei X; Zhou J; Chang L; Sui H; Han Y; Piao D; Sha R; Bai Y
    Cell Death Dis; 2016 Oct; 7(10):e2413. PubMed ID: 27735951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90α in human colorectal cancer.
    Lee SJ; Lee I; Lee J; Park C; Kang WK
    Br J Cancer; 2014 Jul; 111(3):497-505. PubMed ID: 24945998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOXK2 transcriptionally activating VEGFA induces apatinib resistance in anaplastic thyroid cancer through VEGFA/VEGFR1 pathway.
    Feng H; Jin Z; Liang J; Zhao Q; Zhan L; Yang Z; Yan J; Kuang J; Cheng X; Qiu W
    Oncogene; 2021 Oct; 40(42):6115-6129. PubMed ID: 34489549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ETS variant 5 promotes colorectal cancer angiogenesis by targeting platelet-derived growth factor BB.
    Cheng X; Jin Z; Ji X; Shen X; Feng H; Morgenlander W; Ou B; Wu H; Gao H; Ye F; Zhang Y; Peng Y; Liang J; Jiang Y; Zhang T; Qiu W; Lu X; Zhao R
    Int J Cancer; 2019 Jul; 145(1):179-191. PubMed ID: 30650178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.